Bristol Myers announces data from Phase 3 POETYK PsA-2

Bristol Myers (BMY) Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. The POETYK PsA-2 trial met its primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving ACR20 response compared with placebo at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment was consistent with that established in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials. Additionally, treatment with Sotyktu met important secondary endpoints across PsA disease activity at Week 16, demonstrating improvement across clinical signs and symptoms, extra-articular manifestations and patient-reported outcomes. Significantly more Sotyktu-treated patients achieved a Psoriasis Area and Severity Index 75 response compared with placebo.